GLP-1 analogue, reference only
Semaglutide
Long-acting GLP-1 receptor agonist; ~94% human GLP-1 homology with a C18-diacid albumin tether driving a ~7-day plasma half-life.
Semaglutide is not in our range right now. This page documents it from the literature for research reference only, not for human use. Compounds available to order are listed below.
Specification
- Molecular weight
- 4,113.58 Da
- Half-life
- 6.9 d
- Research area
- GLP-1 analogue
Also called Ozempic, Wegovy, Rybelsus, NN9535
~145–168 h in humans (SC, terminal). Long t½ driven by C18 fatty-diacid linker at Lys26 binding plasma albumin and resistance to DPP-4 via Aib8 substitution. Lau et al., J Med Chem 2015.
About the research
Semaglutide (NN9535) is a fatty-acid-acylated GLP-1 analog engineered by Novo Nordisk for once-weekly subcutaneous dosing. The Aib8 substitution blocks DPP-4 cleavage and a fatty-diacid moiety on Lys26 binds serum albumin, producing a ~165-hour terminal half-life — among the longest of any approved peptide therapeutic. It is the most-studied incretin agonist of the decade, with applications spanning glycemic, cardiometabolic, hepatic, and CNS research.
Mechanism, reported research areas, literature dose ranges and co-factor studies are on the research page, with sources. Nothing there is a claim about this product.
Read the Semaglutide research overview- Glycemic regulation models in T2D research
- Body-weight and adiposity studies in DIO rodent models
- Cardiovascular outcome surrogates (LDL, blood pressure, hsCRP)
- Emerging neuroprotection research (Alzheimer's, Parkinson's models)
- Reported research areas, from the literature. Not product claims.
In stock now
All products
Wolverine Blend€119.90Repair
